Tenofovir News and Research

RSS

Scientists now close to eliminating mother-baby HIV transmission, says leading researcher

Quarraisha Abdool Karim has spent the past three decades studying HIV and AIDS. She has become one of the world's leading epidemiologists and made major contributions to the global understanding of how HIV affects young women.

24 Nov 2021

Hepatitis B in newborns is a public health issue in the Pacific islands

The Pacific island nations are falling back on immunization targets, especially those for diseases spread through mother-to-child transmission, according to WHO officials.

24 Sep 2021

Electronic health systems helped increase HBV screenings during COVID-19 pandemic

At the beginning of the COVID-19 pandemic, community health clinics saw a significant drop in patient visits. Important screenings like those for the hepatitis B virus (HBV) were getting missed, which was a setback for a local program called END B to end the transmission of HBV-;a leading risk factor for liver cancer.

23 Aug 2021

Study: Adolescent girls and young women can and will use HIV prevention products with consistency

Adolescent girls and young women can and will use HIV prevention products with consistency, according to interim results of a study of two different methods: daily use of the antiretroviral (ARV) tablet Truvada as oral pre-exposure prophylaxis (PrEP) and the monthly dapivirine vaginal ring, a new HIV prevention product currently under regulatory review in several countries.

15 Jul 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

New contraceptive gel contains spermicidal, anti-viral, libido-enhancing agents in one formulation

Researchers from North Carolina State University have created a trifunctional contraceptive gel that contains spermicidal, anti-viral and libido-enhancing agents in one formulation.

27 Jan 2021

PrEP prescription can make a positive difference in women who inject drugs

When taken daily, pre-exposure prophylaxis, or PrEP, is a highly effective way to prevent HIV transmission, according to the Centers for Disease Control and Prevention.

16 Dec 2020

New insight into role of autophagy in controlling SARS-CoV-2 infection

A team of researchers at the University of Manitoba in Canada said that nanoparticle targeting of autophagy at the sites could be a potent tool to effectively overcome COVID-19 while preventing the common adverse effects of the drug.

2 Dec 2020

UC researcher receives $443,000 NIH grant to study antiviral drugs

University of Cincinnati pharmaceutical sciences researcher Bingfang Yan, DVM, has received a $443,000 grant from the National Institutes of Health to study how common medicines against viral infections are genetically impacted for therapeutic effectiveness and safety through metabolic conversions in the body.

18 Nov 2020

Cabotegravir highly effective in preventing HIV among women

UNAIDS has been strongly encouraged by groundbreaking new study results showing that the antiretroviral medicine cabotegravir administered by an injection every two months – prevents HIV among women.

10 Nov 2020

HIV drugs cause immune-system changes that can improve resistance to viral infections

Drugs currently used to keep the HIV virus in check also cause immune-system changes that might make humans better able to resist viral infections – but might also cause harmful inflammation, according to a study published today in Cell Reports Medicine.

23 Sep 2020

In vitro testing suggests effective novel drug combinations for SARS-CoV-2

A recent study published on the preprint server bioRxiv* in September 2020 shows the value of drug combinations to enhance the therapeutic and preventive efficacy of such repositioned drugs in standard antiviral therapy.

20 Sep 2020

Researchers launch study to evaluate safety of HIV prevention methods in breastfeeding women

The development of safe and effective HIV prevention methods for cisgender women has long been a global health priority, yet research in women during pregnancy and breastfeeding, when they are most vulnerable to infection, has lagged years behind.

31 Aug 2020

Study identifies three potential drugs to eradicate parasitic worms

Scientists have revealed a way to eradicate parasitic worms by stopping them from using alternative metabolism pathways provided by bacteria that live within them, according to new findings published today in eLife.

12 Aug 2020

NIH study: Long-acting form of HIV prevention drug more effective than daily oral pill

A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by the National Institutes of Health.

7 Jul 2020

Newly identified molecules can help develop COVID-19 therapeutics

SARS-CoV-2, the coronavirus causing the global COVID-19 pandemic, uses a protein called polymerase to replicate its genome inside infected human cells.

30 Jun 2020

Newer antiretroviral drugs may be the safest, most effective HIV treatment during pregnancy

The antiretroviral drugs dolutegravir and emtricitabine/tenofovir alafenamide fumarate (DTG+FTC/TAF) may comprise the safest and most effective HIV treatment regimen currently available during pregnancy, researchers announced today.

11 Mar 2020

PrEP drug levels found to lower among pregnant African adolescent girls and young women

Among African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenofovir were more than 30% lower in those who were pregnant than in those who had recently given birth.

9 Mar 2020

Study to evaluate safety of PrEP and dapivirine ring in pregnant women

A woman who is eight-months pregnant is the first participant to be enrolled into a study evaluating the safety and acceptability of two different HIV prevention approaches when used during pregnancy -- the monthly dapivirine vaginal ring, which is currently under regulatory review, and a daily antiretroviral (ARV) pill called Truvada, an approach already approved in several countries and commonly referred to as PrEP, short for pre-exposure prophylaxis.

10 Feb 2020

New clinical trial to examine the safety of dapivirine vaginal ring and PrEP in pregnant women

The first clinical trial specifically designed to test the safety of the monthly dapivirine vaginal ring in pregnant women has begun in southern and eastern Africa.